| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | -709,000 | 5,562,000 | 2,408,850 | 2,062,156 |
| Loss before benefit from income taxes | -3,571,000 | - | -1,478,358 | -2,334,091 |
| Benefit from income taxes | -401,000 | - | - | - |
| Net income (loss) available to common stockholders, basic | - | - | - | -2,334,091 |
| Net loss | -3,170,000 | 1,947,000 | -1,478,358 | - |
| Earnings per share, basic | -0.05 | 0.03 | -0.02 | -0.04 |
| Earnings per share, diluted | -0.05 | 0.03 | -0.02 | -0.04 |
| Weighted average number of shares outstanding, basic | 62,753,959 | 62,608,598 | 60,731,929 | 54,453,006 |
| Weighted average number of shares outstanding, diluted | 62,753,959 | 67,166,377 | 60,731,929 | 54,453,006 |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)